Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
faldaprevir (32) 32
humans (21) 21
life sciences & biomedicine (21) 21
science & technology (21) 21
simeprevir (19) 19
hepatitis c (18) 18
antiviral agents - therapeutic use (16) 16
sofosbuvir (16) 16
hepatitis c virus (15) 15
ribavirin (14) 14
daclatasvir (13) 13
gastroenterology & hepatology (12) 12
hepacivirus - genetics (12) 12
boceprevir (11) 11
hepacivirus - drug effects (11) 11
hepatitis c, chronic - drug therapy (11) 11
telaprevir (11) 11
antiviral agents - adverse effects (9) 9
genotype (9) 9
protease inhibitors (9) 9
clinical trials as topic (8) 8
hepatitis c - drug therapy (8) 8
oligopeptides - therapeutic use (8) 8
thiazoles - therapeutic use (8) 8
treatment outcome (8) 8
antiviral agents (7) 7
biological response modifiers (7) 7
care and treatment (7) 7
female (7) 7
hiv (7) 7
infectious diseases (7) 7
male (7) 7
middle aged (7) 7
proteases (7) 7
viral nonstructural proteins - antagonists & inhibitors (7) 7
adult (6) 6
asunaprevir (6) 6
drug therapy, combination (6) 6
drug therapy, combination - methods (6) 6
health aspects (6) 6
polyethylene glycols - therapeutic use (6) 6
ribavirin - therapeutic use (6) 6
hepatitis (5) 5
interferon (5) 5
interferon-alpha - therapeutic use (5) 5
pharmacology & pharmacy (5) 5
uridine monophosphate - analogs & derivatives (5) 5
antiviral agents - administration & dosage (4) 4
antiviral agents - pharmacokinetics (4) 4
antiviral agents - pharmacology (4) 4
hepatitis c, chronic - virology (4) 4
heterocyclic compounds, 3-ring (4) 4
medicine & public health (4) 4
oligopeptides (4) 4
oligopeptides - adverse effects (4) 4
oligopeptides - pharmacokinetics (4) 4
pegylated interferon (4) 4
recombinant proteins - therapeutic use (4) 4
sulfonamides (4) 4
thiazoles (4) 4
thiazoles - adverse effects (4) 4
thiazoles - pharmacokinetics (4) 4
antiviral agents - chemistry (3) 3
coinfection (3) 3
danoprevir (3) 3
direct-acting antivirals (3) 3
drug design (3) 3
drug interactions (3) 3
drug therapy (3) 3
genetic aspects (3) 3
genotype 1 (3) 3
healthy volunteers (3) 3
hepacivirus - enzymology (3) 3
hepatitis c, chronic - diagnosis (3) 3
hepatology (3) 3
hiv infections - drug therapy (3) 3
interferon-free (3) 3
japanese (3) 3
ledipasvir (3) 3
liver cirrhosis (3) 3
microbiology (3) 3
oligopeptides - administration & dosage (3) 3
protease inhibitors - therapeutic use (3) 3
risk factors (3) 3
sustained virological response (3) 3
thiazoles - administration & dosage (3) 3
time factors (3) 3
viruses (3) 3
young adult (3) 3
administration, oral (2) 2
aged (2) 2
analysis (2) 2
animals (2) 2
antibiotics. antiinfectious agents. antiparasitic agents (2) 2
antiretroviral therapy, highly active (2) 2
antiretrovirals (2) 2
antiviral (2) 2
antiviral therapy (2) 2
articles and commentaries (2) 2
biological and medical sciences (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Chronic hepatitis C： This and the new era of treatment
by Bertino, Gaetano and Ardiri, Annalisa and Proiti, Maria and Rigano, Giuseppe and Frazzetto, Evelise and Demma, Shirin and Ruggeri, Maria Irene and Scuderi, Laura and Malaguarnera, Giulia and Bertino, Nicoletta and Rapisarda, Venerando and Di Carlo, Isidoro and Toro, Adriana and Salomone, Federico and Malaguarnera, Mariano and Bertino, Emanuele and Malaguarnera, Michele
World journal of hepatology, ISSN 1948-5182, 2016, Volume 8, Issue 2, pp. 92 - 106
Simeprevir | Nucleosideinhibitors | Faldaprevir;Ritonavir | Ledipasvir | Telaprevir | agents | Dasabuvir | Daclatasvir | Boceprevir | Ombitasvir | Direct-acting | antiviral | Sofosbuvir | HepatitisC | Ritonavir | Faldaprevir | Nucleoside inhibitors | Direct-acting antiviral agents | Hepatitis C | Topic Highlight
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text HCV direct‐acting antiviral agents: the best interferon‐free combinations
by Schinazi, Raymond and Halfon, Philippe and Marcellin, Patrick and Asselah, Tarik
Liver international, ISSN 1478-3223, 02/2014, Volume 34, Issue 1, pp. 69 - 78
sofosbuvir | faldaprevir | ribavirin | simeprevir | pegylated interferon | asunaprevir | daclatasvir | Daclatasvir | Simeprevir | Pegylated interferon | Faldaprevir | Asunaprevir | Ribavirin | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Heterocyclic Compounds, 3-Ring | Hepatitis C - drug therapy | Oligopeptides | Isoquinolines | Humans | Hepacivirus - genetics | Drug Discovery - methods | Disease Eradication - methods | Recombinant Proteins | Protease Inhibitors - pharmacology | Thiazoles | Hepacivirus - drug effects | Virus Replication - drug effects | Antiviral Agents - pharmacology | Polyethylene Glycols | Antiviral Agents - therapeutic use | Interferon-alpha | Clinical Trials as Topic | Disease Eradication - trends | Drug Therapy, Combination - methods | Drug Therapy, Combination - trends | Imidazoles | Sulfonamides | Uridine Monophosphate - analogs & derivatives | Viral Nonstructural Proteins - antagonists & inhibitors | Virus Replication - physiology | Hepatitis C virus | Biological response modifiers | Interferon | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries
by Andrew Hill and Saye Khoo and Joe Fortunak and Bryony Simmons and Nathan Ford
Clinical infectious diseases, ISSN 1058-4838, 4/2014, Volume 58, Issue 7, pp. 928 - 936
Antiretrovirals | HIV | Cost estimates | Antivirals | Raw material costs | Raw materials | ARTICLES AND COMMENTARIES | Hepatitis C | Dosage | Hepacivirus | Production costs | sofosbuvir | faldaprevir | ribavirin | simeprevir | daclatasvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Antiviral agents | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Heterocyclic Compounds, 3-Ring - economics | Simeprevir | Oligopeptides - economics | Hepatitis C - drug therapy | Ribavirin - economics | Humans | Imidazoles - chemistry | Uridine Monophosphate - chemistry | Uridine Monophosphate - economics | Thiazoles - therapeutic use | Health Services Accessibility - economics | Oligopeptides - therapeutic use | Antiviral Agents - chemistry | Drug Industry - economics | Imidazoles - therapeutic use | Drug Therapy, Combination | Oligopeptides - chemistry | Thiazoles - economics | Uridine Monophosphate - therapeutic use | Sulfonamides - chemistry | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Ribavirin - chemistry | Anti-HIV Agents - chemistry | Sulfonamides - therapeutic use | Imidazoles - economics | Heterocyclic Compounds, 3-Ring - chemistry | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - economics | Uridine Monophosphate - analogs & derivatives | Thiazoles - chemistry | Developing Countries | Antiviral Agents - economics | Sofosbuvir | Economic aspects | Production management | Care and treatment | Hepatitis | Antiviral drugs | Medical treatment | Developing countries--LDCs | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C
by Gutierrez, J. A and Lawitz, E. J and Poordad, F
Journal of viral hepatitis, ISSN 1352-0504, 11/2015, Volume 22, Issue 11, pp. 861 - 870
protease inhibitor | beclabuvir | direct‐acting antivirals | ribavirin | ombitasvir | hepatitis C | NS5A inhibitor | asunaprevir | GS‐9669 | elbasvir | paritaprevir | daclatasvir | ledipasvir | sofosbuvir | faldaprevir | simeprevir | RNA polymerase inhibitor | grazoprevir | genotype 1 | dasabuvir | resistance‐associated variants | resistance-associated variants | direct-acting antivirals | GS-9669 | Gastroenterology & Hepatology | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Virology | Enzyme Inhibitors - administration & dosage | Drug Therapy, Combination - methods | Administration, Oral | Humans | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Viral Nonstructural Proteins - antagonists & inhibitors | Antiviral Agents - administration & dosage | Care and treatment | Protease inhibitors | Proteases | Interferon | Hepatitis C | Biological response modifiers | Hepatitis C virus | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and efficacy of faldaprevir in combination with pegylated interferon α‐2b and ribavirin in Japanese patients with genotype‐1 chronic hepatitis C virus infection
by Nishiguchi, Shuhei and Urano, Yasuhisa and Suzaki, Keiko and Taniguchi, Atsushi and Scherer, Joseph and Berger, Kristi L and Quinson, Anne‐Marie and Stern, Jerry O and Omata, Masao
Hepatology research, ISSN 1386-6346, 03/2017, Volume 47, Issue 3, pp. E142 - E151
treatment‐experienced | treatment‐naïve | faldaprevir | relapser | Japanese | phase III | treatment-experienced | treatment-naïve
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy
by Asselah, Tarik
Journal of hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 2, pp. 435 - 438
Gastroenterology and Hepatology | Daclatasvir | Faldaprevir | Simeprevir | Sofosbuvir | Direct-acting antivirals | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antiviral Agents - therapeutic use | Humans | Uridine Monophosphate - analogs & derivatives | Hepacivirus - genetics | Female | Male | Imidazoles - therapeutic use | Hepatitis C, Chronic - drug therapy | Viral Nonstructural Proteins - antagonists & inhibitors | Hepatitis C virus | Antiviral agents | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
by Shah, Nihar and Pierce, Tracey and Kowdley, Kris V
Expert opinion on investigational drugs, ISSN 1354-3784, 09/2013, Volume 22, Issue 9, pp. 1107 - 1121
partial responders | boceprevir | NS5A inhibitors | null responders | pegylated interferon | relapsers | SVR | ABT-333 | danoprevir | simeprevir | telaprevir | hepatitis C virus | protease inhibitors | ABT-450 | cirrhosis | ribavirin | NS5B polymerase inhibitors | treatment naïve | asunaprevir | resistance | daclatasvir | ABT-267 | directly acting antiviral agents | ledipasvir | sofosbuvir | faldaprevir | cyclophilin inhibitors | mericitabine | Cyclophilin inhibitors | Simeprevir | Ledipasvir | Faldaprevir | Null responders | Telaprevir | Ribavirin | Daclatasvir | Treatment naïve | Directly acting antiviral agents | Asunaprevir | Danoprevir | Pegylated interferon | Partial responders | Mericitabine | Resistance | Cirrhosis | Boceprevir | Relapsers | Protease inhibitors | Hepatitis C virus | Sofosbuvir | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Antiviral Agents - pharmacology | Antiviral Agents - therapeutic use | United States | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Clinical Trials as Topic | Drug Approval | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Drug Design | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Interferon free therapy with direct acting antivirals for HCV
by Asselah, Tarik and Marcellin, Patrick
Liver international, ISSN 1478-3223, 02/2013, Volume 33, Issue 1, pp. 93 - 104
sofosbuvir | faldaprevir | simeprevir | ribavirin | NS5A inhibitors | NS5B polymerase inhibitors | protease inhibitors | asunaprevir | daclatasvir | Daclatasvir | Simeprevir | Protease inhibitors | Faldaprevir | Asunaprevir | Ribavirin | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Recombinant Proteins - therapeutic use | Antiviral Agents - therapeutic use | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hepacivirus - genetics | Models, Molecular | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Hepacivirus - enzymology | Serine Proteinase Inhibitors - chemistry | Antiviral Agents - chemistry | Serine Proteinase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Drug Design | Molecular Structure | Drug Therapy, Combination | Viral Nonstructural Proteins - antagonists & inhibitors | Interferon | Biological response modifiers | Hepatitis C virus | Proteases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effect of Steady‐State Faldaprevir on Pharmacokinetics of Atorvastatin or Rosuvastatin in Healthy Volunteers: A Prospective Open‐Label, Fixed‐Sequence Crossover Study
by Huang, Fenglei and Marzin, Kristell and Koenen, Rüdiger and Kammerer, Klaus Peter and Strelkowa, Natalja and Elgadi, Mabrouk and Quinson, Anne‐Marie and Haertter, Sebastian
Journal of clinical pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Atorvastatin - blood | Rosuvastatin Calcium - blood | Serine Proteinase Inhibitors - pharmacology | Antiviral Agents - pharmacology | Atorvastatin - adverse effects | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Atorvastatin - analogs & derivatives | Oligopeptides - pharmacology | Atorvastatin - pharmacokinetics | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV
by Dieterich, Douglas and Nelson, Mark and Soriano, Vicente and Arastéh, Keikawus and Guardiola, Josep M and Rockstroh, Jürgen K and Bhagani, Sanjay and Laguno, Montserrat and Tural, Cristina and Ingiliz, Patrick and Jain, Mamta K and Stern, Jerry O and Manero, Montserrat and Vinisko, Richard and Kort, Jens and STARTVerso4 study group
AIDS (London), ISSN 0269-9370, 03/2015, Volume 29, Issue 5, pp. 571 - 581
SVR12 | faldaprevir | NS3/4A protease inhibitor | HIV | hepatitis C virus genotype 1 | Recombinant Proteins - therapeutic use | Viremia - diagnosis | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Thiazoles - therapeutic use | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Young Adult | Drug Therapy, Combination - methods | Adolescent | HIV Infections - complications | Adult | Aged | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue
by Liang, Li and Hu, Jianping and Du, Wenyi and Zuo, Ke and Liu, Wei and Gou, Xiaojun
Shengwu gongcheng xuebao, ISSN 1000-3061, 05/2016, Volume 32, Issue 5, pp. 669 - 682
Faldaprevir analogue molecule | Binding free energy | Molecular dynamics simulation | HCV NS3/4A protease | Conformational change
Journal Article
Details down arrow
12. Full Text Management of HCV patients with cirrhosis with direct acting antivirals
by Boccaccio, Vincenzo and Bruno, Savino
Liver international, ISSN 1478-3223, 02/2014, Volume 34, Issue 1, pp. 38 - 45
sofosbuvir | faldaprevir | boceprevir | simeprevir | HCV‐related cirrhosis | direct acting antivirals | telaprevir | sustained virological response | hepatitis C virus | Simeprevir | Boceprevir | Faldaprevir | Sustained virological response | Direct acting antivirals | Telaprevir | HCV-related cirrhosis | Hepatitis C virus | Sofosbuvir | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Heterocyclic Compounds, 3-Ring | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Hepatitis C - drug therapy | Oligopeptides | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Clinical Trials as Topic | Drug Therapy, Combination - methods | Algorithms | Time Factors | Sulfonamides | Uridine Monophosphate - analogs & derivatives | Thiazoles | Liver Cirrhosis - pathology | Drug Therapy, Combination - statistics & numerical data | Hepatitis C - complications | Hepatitis C - pathology | Antiviral agents | Biological response modifiers | Hepatitis C | Liver cirrhosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights